Showing 1 to 2 of 2 results


Teva's Market Cap Falls $6 Billion Despite Positive 2024 Results
Teva Pharmaceutical Industries' market cap fell by roughly $6 billion to $18.8 billion after its 2025 profit guidance disappointed investors despite positive 2024 results that exceeded expectations, prompting CEO Richard Francis to highlight the company's growth strategy focusing on branded drugs.
Teva's Market Cap Falls $6 Billion Despite Positive 2024 Results
Teva Pharmaceutical Industries' market cap fell by roughly $6 billion to $18.8 billion after its 2025 profit guidance disappointed investors despite positive 2024 results that exceeded expectations, prompting CEO Richard Francis to highlight the company's growth strategy focusing on branded drugs.
Progress
52% Bias Score

Teva Exceeds 2024 Expectations but 2025 Outlook Disappoints
Teva Pharmaceutical Industries reported exceeding 2024 financial results with $4.2 billion in Q4 revenue and $16.5 billion in full-year revenue; however, its share price fell almost 10% due to a less optimistic 2025 outlook of $16.8-17.4 billion in revenue and $2.35-2.65 non-GAAP EPS.

Teva Exceeds 2024 Expectations but 2025 Outlook Disappoints
Teva Pharmaceutical Industries reported exceeding 2024 financial results with $4.2 billion in Q4 revenue and $16.5 billion in full-year revenue; however, its share price fell almost 10% due to a less optimistic 2025 outlook of $16.8-17.4 billion in revenue and $2.35-2.65 non-GAAP EPS.
Progress
36% Bias Score
Showing 1 to 2 of 2 results